ENPP2 and idiopathic pulmonary fibrosis: Idiopathic pulmonary fibrosis is the first emerging target disease for ATX inhibition as genetic and pharmacologic targeting of the ATX-LPA axis has been shown to attenuate disease development in animal experiments, which has prompted clinical trials of ATX inhibitors against idiopathic pulmonary fibrosis [15, 61].